Northland Securities analyst Suraj Kalia maintained a Hold rating on Insulet Corp (PODD – Research Report) today and set a price target of $110. The company’s shares closed yesterday at $117.93, close to its 52-week high of $126.71.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 9.5% and a 56.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insulet Corp with a $128.67 average price target.
Based on Insulet Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $4.38 million. In comparison, last year the company had a GAAP net loss of $1.69 million.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.